CSPC Pharmaceutical Group Limited clinical trials

The registry lists 344 studies whose lead sponsor is CSPC Pharmaceutical Group Limited or one of 12 companies grouped under it. 160 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 344. Browse all 344 →

• Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and AboveNot yet recruitingNCT07892989Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy ParticipantsRecruitingNCT07532655Phase 1

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.Not yet recruitingNCT07881991Phase 2

  Sponsor listed in the registry: CSPC Ouyi Pharmaceutical Co., Ltd.

• SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaRecruitingNCT07254585Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07879911Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsNot yet recruitingNCT07857135Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsNot yet recruitingNCT07840729Phase 1

  Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group

• A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube CancersRecruitingNCT07708753Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07833735Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Effect of Food of SYH2056 in Healthy SubjectsNot yet recruitingNCT07771777Phase 1

  Sponsor listed in the registry: InnovStone Therapeutics Limited

• Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.Not yet recruitingNCT07803991Phase 2

  Sponsor listed in the registry: CSPC Ouyi Pharmaceutical Co., Ltd.

• A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast CancerNot yet recruitingNCT07805135Phase 3

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or MetforminNot yet recruitingNCT07796477Phase 2

  Sponsor listed in the registry: CSPC Ouyi Pharmaceutical Co., Ltd.

• A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.Not yet recruitingNCT07798193Phase 2

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian CancerRecruitingNCT07714668Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYH2092 Injection in Healthy ParticipantsNot yet recruitingNCT07776041Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsRecruitingNCT07280832Phase 1/2

  Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group

• A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia GravisRecruitingNCT06688435Phase 1

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants.RecruitingNCT07756996Phase 1

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCCNot yet recruitingNCT07758621Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid TumorsRecruitingNCT07744763Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial HypercholesterolemiaRecruitingNCT07591298Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaRecruitingNCT07695597Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.RecruitingNCT07519109Phase 1

  Sponsor listed in the registry: CSPC Ouyi Pharmaceutical Co., Ltd.

• A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial LesionsNot yet recruitingNCT07702656Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver FunctionRecruitingNCT07694843Phase 1

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal FunctionRecruitingNCT07694869Phase 1

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• SYH2095 for Advanced Malignant Tumors: Phase I StudyNot yet recruitingNCT07692776

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)RecruitingNCT07465263Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid TumorsNot yet recruitingNCT07684261

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid HemangioendotheliomaNot yet recruitingNCT07684287Phase 2

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）RecruitingNCT06927986Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07672223Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Clinical Study of SYS6023 Combination Therapy for Advanced Breast CancerRecruitingNCT07597629Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 TabletsRecruitingNCT07647783Phase 1

  Sponsor listed in the registry: InnovStone Therapeutics Limited

• SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）Not yet recruitingNCT07633873Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)Not yet recruitingNCT07640217Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant HypertensionNot yet recruitingNCT07635914Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061RecruitingNCT07241910Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic AcidNot yet recruitingNCT07623915Phase 3

  Sponsor listed in the registry: CSPC Ouyi Pharmaceutical Co., Ltd.

• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With AcromegalyNot yet recruitingNCT07623824Phase 3

  Sponsor listed in the registry: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

• SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid TumorsNot yet recruitingNCT07622225Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of JMT203 in Patients With Cancer CachexiaRecruitingNCT06868849Phase 1/2

  Sponsor listed in the registry: Shanghai JMT-Bio Inc. · Shanghai JMT-Bio Inc. — acquired company within the CSPC Pharmaceutical Group Limited group

• A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07600021Phase 2

  Sponsor listed in the registry: InnovStone Therapeutics Limited

• A Study of SYS6051 in Subjects With Advanced Solid TumorsNot yet recruitingNCT07591285Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07376382Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Comparative Pharmacokinetic Study of CM326 in Healthy SubjectsNot yet recruitingNCT07560033Phase 1

  Sponsor listed in the registry: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. — acquired company within the CSPC Pharmaceutical Group Limited group

• A Phase III Study of CM326 in Subjects With Moderate to Severe AsthmaRecruitingNCT07372287Phase 3

  Sponsor listed in the registry: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. — acquired company within the CSPC Pharmaceutical Group Limited group